Company registration number 06413394 (England and Wales)
CAPITA HEALTH HOLDINGS LIMITED
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
CAPITA HEALTH HOLDINGS LIMITED
COMPANY INFORMATION
Directors
Capita Corporate Director Limited
G Bate-Williams
Secretary
Capita Group Secretary Limited
Company number
06413394
Registered office
First Floor
2 Kingdom Street
Paddington
London
England
W2 6BD
Banker
Barclays Bank PLC
1 Churchill Place
London
United Kingdom
E14 5HP
CAPITA HEALTH HOLDINGS LIMITED
CONTENTS
Page
Strategic report
1 - 6
Directors' report
7 - 8
Income statement
9
Balance sheet
10 - 11
Statement of changes in equity
12
Notes to the financial statements
13 - 22
CAPITA HEALTH HOLDINGS LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 1 -

The Directors present their Strategic report and financial statements for the year ended 31 December 2025.

 

Capita Health Holdings Limited ('the Company') is a wholly owned subsidiary (indirectly held) of Capita plc. Capita plc, along with all its subsidiaries' is hereafter referred to as 'the Group'.

Principal activities

The principal activity of the Company is that of a holding and investment Company. There have not been any significant changes in the Company's principal activities in the year under review. The Directors are not aware, at the date of this report, of any likely major changes in the Company's activities in the next year.

Review of the business

As shown in Company's income statement on page 9, the Company's profit before tax has decreased from £81,660,364 in 2024 to £399,360 in 2025. The decrease reflects the impact of significant income recognised in 2024, comprising dividend income from subsidiaries and the recognition of a material intercompany loan payable waiver as other income following a Group debt restructuring.

The balance sheet on pages 10 to 11 of the financial statements shows the financial position at the year end. Net assets have increased from £5,259,483 in 2024 to £5,559,002 in 2025 due to profit generated during the year.

Details of the amounts owed by/to its parent company and fellow subsidiary companies are shown in notes 10 and 11 to the financial statements.

 

Although the Company is in a net current liability position, the ultimate parent company has stated that it will provide continuing financial assistance to the Company for the foreseeable future.

 

The Company has not identified any key performance indicators due to the nature of its operations as a holding company and as described in the principal activities above.

Principal risks and uncertainties

The Company is exposed to a wide range of risks that, should they materialise, could have a detrimental impact on financial performance, reputation or operational resilience. The Company’s risk management framework provides a consistent approach to the identification, assessment, monitoring and reporting of risks and opportunities. The risk management process is based on risk registers and risk reporting at the established risk governance committees. Key risks are documented in the risk registers and have assigned risk owners who review them regularly, and report on them on at least a half-yearly basis at divisional and functional risk governance committees, Executive risk and Ethics Committee and Audit and Risk Committee. The effectiveness of existing controls is evaluated by the Company to determine whether any further mitigating actions are needed to manage the risk level to within the risk appetite set by the Capita plc Board.

 

The principal risks for the Company are:

 

Financial stability and resilience

Our ability to maintain financial resilience and achieve financial targets.

 

Cyber security

Protect our systems, networks and programs from unauthorised use and access.

 

Environment, social and governance

Comply with regulatory and contractual requirements to drive a purpose driven organisation with the right focus on governance.

 

Data governance and data privacy

Manage our data effectively (both clients' and the Company's) as a strategic asset across the organisation.

 

As a subsidiary of Capita plc, the Company is subject to controls and risk governance techniques applied across all the Group's businesses. Details of the specific risk assessments and mitigating actions are outlined on pages 81-85 of the Group's 2025 Annual Report.

CAPITA HEALTH HOLDINGS LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -
Section 172 statement

Capita plc’s section 172 statement applies to its Divisions and the Company to the extent it relates to the Company’s activities. Common policies and practices are applied across the Group through divisional management teams and a common governance framework. The following disclosure describes how the Directors have regard to the matters set out in section 172(1)(a) to (f) and forms the Directors’ statement as required under section 414CZA of the Companies Act 2006. Further details of the Group’s approach to each stakeholder are provided in Capita plc’s section 172 statement on pages 59-62 of Capita plc’s 2025 Annual Report.

 

Our People

 

Why this relationship matters

Our colleagues are central to the delivery of the Group’s strategy, the embedding of a values-based culture, and the provision of high-quality products and services that meet client expectations.

 

Their key priorities and expectations

Colleagues’ priorities include opportunities for learning, development and career progression; a positive and inclusive workplace culture; fair and transparent pay and reward; support for health and wellbeing; flexible ways of working; and open, two-way communication with leadership, including clear visibility of strategy, change programmes and decision-making.

 

How we engaged

 

Topics of engagement

 

Outcomes and actions

The 2025 all-colleague survey reported an Employee Net Promoter Score (eNPS) of -22, representing an eleven-point improvement on the 2024 survey. While this indicates improving colleague sentiment, the Board recognises that overall survey indicators show engagement remains an area of focus. Survey insights have informed targeted action planning at Group, divisional and local levels.

 

During the year, the Group continued to progress its multi-year culture programme, building on foundations established in 2024 to rally, reset and embed Capita’s culture. This included the further mobilisation of more than 250 Culture Accelerators globally, mandated management and leadership development, and the embedding of refreshed Group values and the launch of an employee playbook to support consistent behaviours and ways of working. The Group also introduced Celebrate!, a recognition platform designed to reward and celebrate colleagues and reinforce behaviours aligned to Capita’s values across the organisation. Capita continued to strengthen its focus on inclusion and fair reward. Gender pay gap performance improved compared to the prior year, and the Group continued its voluntary disclosure of ethnicity pay gap data and, for the first time, disability pay gap data. Since reporting commenced in 2017, Capita has reduced its median gender pay gap by more than ten percentage points.

 

Engagement with colleagues on pay, progression and reward transparency was strengthened through dedicated workforce engagement sessions during the year Promotion of the Speak Up policy continued across the organisation, reinforcing the Group’s commitment to ethical behaviour, openness and psychological safety.

CAPITA HEALTH HOLDINGS LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 3 -
Section 172 statement (continued)

Risks to stakeholder relationship

 

Key metrics

Voluntary attrition, eNPS, employee engagement index and colleague survey completion level.

Clients and customers

 

Why this relationship matters

Clients and customers rely on Capita for the consistent and timely delivery of critical services. Capita’s reputation, contract performance and long-term success depend on meeting their service expectations and supporting effective transformation outcomes.

 

Their key priorities and expectations

High-quality service delivery; delivery of transformation projects within agreed timeframes; and responsible, ethical and sustainable business credentials.

 

How we engaged

 

Topics of engagement

Outcomes and actions

Feedback provided to business units to address any issues raised; client value proposition teams supporting divisions with co-creation ideas; direct customer and sector feedback; and senior client partner programme undertaking client-focused growth sprints and account plans to build understanding of client issues and ideas to help address them.

 

Risks to stakeholder relationship

 

Key metrics

Customer NPS; specific feedback on client engagements.

CAPITA HEALTH HOLDINGS LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 4 -
Section 172 statement (continued)

Suppliers and Partners

Why this relationship matters

At Capita, our suppliers and partners including leading hyperscalers, play a pivotal role in delivering our purpose. By collaborating with organisations that share our values, we maintain high standards, ensure operational excellence, and achieve outcomes aligned with our social, economic, and environmental commitments. Our partnerships, particularly with hyperscalers including AWS, Microsoft, Salesforce and ServiceNow, enhance our ability to innovate and deliver cutting-edge digital solutions.

 

We will continually review our supply base to ensure it delivers better outcomes for customers while addressing the need to reduce supply chain complexity and improve service quality.

 

Their key priorities and expectations

 

How we engaged

 

Topics of engagement

 

CAPITA HEALTH HOLDINGS LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 5 -
Section 172 statement (continued)

Outcomes and actions

Our Supplier Charter, which is available on our website, remains central to Capita’s approach to supplier relationships and sets out the standards and behaviours expected of suppliers, including acting ethically, providing safe working conditions, treating workers with dignity and respect, and operating in an environmentally responsible manner. The Group seeks to work with suppliers and partners that share its values and support delivery of its purpose to create better outcomes.

 

As part of its responsible business commitments, Capita manages and monitors a range of supply chain-related metrics, including sustainability performance, spend with SMEs, VCSEs and diverse-owned businesses, and modern slavery risk.

 

During the year, procurement governance and risk management arrangements were strengthened through the introduction of enhanced supplier due diligence and a new supplier risk assessment framework, supported by a centralised supplier relationship management platform. These controls improve visibility across the supplier lifecycle and support the identification, monitoring and mitigation of risks relating to human rights, modern slavery, ethical conduct and regulatory compliance.

 

During 2025, 97% of Group suppliers were paid within 60 days.

 

Risks to stakeholder relationship

 

Key metrics

Percentage of supplier payments made within agreed terms; SME spend allocation; and supplier diversity profile.

 

Society

 

Why this relationship matters

Capita is a provider of key services to government impacting a large proportion of the population.

 

Their key priorities and expectations

Social value; community engagement; diversity, equity and inclusion; climate change; data privacy and security, AI, business ethics; accreditations and benchmarking; and cost-of-living pressures

 

How we engaged

 

Topics of engagement

CAPITA HEALTH HOLDINGS LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 6 -

Section 172 statement (continued)

 

Outcomes and actions

Community engagement programme such as Social Shifters; Business in the Community’s Opening Doors campaign, a flagship initiative championing inclusive recruitment across UK workplaces. Listed on the Forbes Global list of top employers for women for the third consecutive year; our gender pay gap has improved by 11.10% since we began reporting. We achieved Onvero’s Gold Talent Inclusion and Diversity Evaluation (TIDE) Award, maintained a Disability Confident Employer (level 3) recognition across the Group and Armed Forces Covenant Gold Employer Recognition Award, received Carbon Disclosure Project (CDP) ranking of B, EcoVadis Committed badge and the Charities Trust’s Payroll Giving Platinum Quality Mark Award.

 

Risks to stakeholder relationship

 

Key metrics

Community investment, workforce diversity and ethnicity data, including pay gaps, external indices performance such as EcoVadis.

 

 

 

On behalf of the board

 

 

G Bate-Williams
Director
15 September 2026
CAPITA HEALTH HOLDINGS LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 7 -

The Directors present their Directors' Report and Financial statements for the year ended 31 December 2025.

Results and dividends

The results for the year are set out on page 9.

No dividends were paid out or proposed during the year (2024 : £nil).

Directors

The Directors, who held office during the year and up to the date of signature of the financial statements were as follows:

Capita Corporate Director Limited
G Bate-Williams
Qualifying third party indemnity provisions

The Company has granted an indemnity to the directors of the Company against liability in respect of proceedings brought by third parties, subject to the conditions set out in the Companies Act 2006. Such qualifying third-party indemnity provisions remains in force as at the date of approving the directors' report.

Political donations

The Company made no political donations and incurred no political expenditure during the year (2024: £nil).

Statement of Directors' responsibilities

The Directors are responsible for preparing the Strategic report, the Directors’ report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law they have elected to prepare the financial statements in accordance with United Kingdom ('UK') accounting standards and applicable law (UK Generally Accepted Accounting Practice), including FRS 101 Reduced Disclosure Framework.

Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of its profit or loss for that period. In preparing these financial statements, the Directors are required to:

 

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company’s transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the Company and to prevent and detect fraud and other irregularities.

 

 

 

 

 

 

 

CAPITA HEALTH HOLDINGS LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 8 -
Strategic report

In accordance with s414c(11) of the Companies Act 2006, the Company has set out certain information in its Strategic report that is otherwise required to be disclosed in the Directors' report. This includes information regarding results and activities and a description of the principle risks and uncertainties facing the Company.

On behalf of the board
G Bate-Williams
Director
15 September 2026
CAPITA HEALTH HOLDINGS LIMITED
INCOME STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 9 -
2025
2024
Notes
£
£
Administrative expenses
-
0
(44)
Investment income
3
-
0
27,140,282
Other income
4
-
0
52,000,013
Impairments
5
-
0
(101)
Net finance income
6
399,360
2,520,214
Profit before tax
399,360
81,660,364
Income tax charge
7
(99,841)
(630,038)
Profit and total comprehensive income for the year
299,519
81,030,326

The income statement has been prepared on the basis that all operations are continuing operations.

The notes and information on pages 13 to 22 form an integral part of these financial statements.

CAPITA HEALTH HOLDINGS LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2025
31 December 2025
- 10 -
2025
2024
Notes
£
£
Non-current assets
Investments in subsidiaries
8
5,283,013
5,283,013
Trade and other receivables
10
1,005,872
-
0
6,288,885
5,283,013
Current assets
Trade and other receivables
10
-
0
15,111,526
-
15,111,526
Total assets
6,288,885
20,394,539
Current liabilities
Trade and other payables
11
-
14,299,366
Income tax payable
729,883
835,690
Total liabilities
729,883
15,135,056
Net assets
5,559,002
5,259,483
CAPITA HEALTH HOLDINGS LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 DECEMBER 2025
31 December 2025
2025
2024
Notes
£
£
- 11 -
Capital and reserves
Issued share capital
14
1
20,000
Share premium
15
-
0
1,980,000
Retained earnings
5,559,001
3,259,483
Total equity
5,559,002
5,259,483

The notes and information on pages 13 to 22 form an integral part of these financial statements.

For the financial year ended 31 December 2025, the company was entitled to exemption from audit under section 479A of the Companies Act 2006 relating to subsidiary companies.

The Directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements were approved by the board of directors and authorised for issue on 15 September 2026 and are signed on its behalf by:
G Bate-Williams
Director
Company registration number 06413394 (England and Wales)
CAPITA HEALTH HOLDINGS LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2025
- 12 -
Share capital
Share premium
Retained earnings
Total equity
£
£
£
£
At 1 January 2024
20,000
1,980,000
(77,770,843)
(75,770,843)
Profit for the year
-
-
81,030,326
81,030,326
At 31 December 2024
20,000
1,980,000
3,259,483
5,259,483
Profit for the year
-
-
299,519
299,519
Transactions with owners:
Capital reduction
(19,999)
(1,980,000)
1,999,999
-
0
At 31 December 2025
1
-
0
5,559,001
5,559,002
Share capital

The balance classified as share capital is the nominal proceeds on issue of the Company's equity share capital, comprising 1 ordinary shares of £1. During the year, the Company reduced its share capital from £20,000 to £1 by cancelling 19,999 ordinary shares of £1 each.

Share premium

The amount paid to the Company by shareholders, in cash or other consideration, over and above the nominal value of the shares issued to them less issuance costs. During the year, the Company reduced its share premium from £1,980,000 to £nil.

Retained earnings

Net profits accumulated in the Company after dividends are paid.

The notes and information on pages 13 to 22 form an integral part of these financial statements.

CAPITA HEALTH HOLDINGS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 13 -
1
Accounting policies
1.1
Basis of preparation

Capita Health Holdings Limited is a Company incorporated, registered and domiciled in the England and Wales.

 

The financial statements are prepared under the historical cost basis except where stated otherwise and in accordance with applicable accounting standards.

 

In determining the appropriate basis of preparation for the annual report and financial statements for the year ended 31 December 2025, the Company’s Directors (‘the Directors’) are required to consider whether the Company can continue in operational existence for the foreseeable future. The Directors have concluded that it is appropriate to adopt the going concern basis, having undertaken a rigorous assessment as set out below.

 

Accounting standards require that ‘the foreseeable future’ for going concern assessment covers a period of at least twelve months from the date of approval of these financial statements. The Directors have considered the period from the date of approval of these financial statements to 31 December 2027 (‘the going concern period’) and which aligns to the period considered by the Directors of the ultimate parent company, Capita plc.

Directors’ assessment

The financial forecasts used for the going concern assessment are derived from financial projections for 2026-2028 for the Company which have been subject to review and challenge by management and the Directors. The Directors have approved the projections.

 

Inter-dependency with other entities in the group headed by Capita plc (‘the Group’)

The Director’s assessment of going concern has considered the extent to which the Company’s ability to remain a going concern is inter-dependent with that of the Group. The Company has dependency with the Group in respect of the following:

 

Despite the Company being in a net current liability position, the ultimate parent company, Capita plc, has stated that it will provide continuing financial support as necessary and to the extent it is able to do so during the going concern assessment period.

 

The Company’s financial projections are dependent on the Group providing additional financial support over the period the going concern period. Capita plc has indicated its intention to provide financial support to the Company in order to meet its liabilities as and when they fall due in the going concern assessment period.

 

As with any company placing reliance on other group entities for financial support, the Directors acknowledge that there can be no certainty that this support will continue although, at the date of approval of these financial statements, they have no reason to believe that it will not do so.

 

Given the reliance the Company has with the Group, the Directors have considered the financial position of the ultimate parent company as disclosed in its most recent condensed consolidated financial statements, being for the six months ended 30 June 2026.

 

 

The financial statements have been prepared under the historical cost basis except where stated otherwise and in accordance with applicable accounting standards.

CAPITA HEALTH HOLDINGS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 14 -

Basis of Preparation (continued)

 

Ultimate parent undertaking – Capita plc

The Capita plc Board (‘the Board’) concluded that it was appropriate to adopt the going concern basis, having undertaken a rigorous assessment of the financial forecasts, key uncertainties, sensitivities, and mitigations when preparing the Group’s condensed consolidated financial statements at 30 June 2026. These condensed consolidated financial statements were approved by the Board on 3 August 2026 and are available on the Group’s website (www.capita.com/investors). Below is a summary of the position at 3 August 2026:

Accounting standards require that ‘the foreseeable future’ for going concern assessment covers a period of at least twelve months from the date of approval of the condensed consolidated financial statements. The Board has considered the period from the date of approval of these condensed consolidated financial statements to 31 December 2027, which aligns with the year end and covenant test date for the Group.

The base case financial forecasts used in the Group going concern assessment are derived from the 2026-2028 business plan as approved by the Board in March 2026 and subsequently updated for new funding arrangements, the disposal of the private sector contact centre business and trading conditions.

Under the base case scenario, the disposal of the private sector contact centre business and the material overhead reduction it enables as further complexity is removed from the Group, facilitates growth in profit and cash flow over the medium term. The phasing of the overhead reduction in 2026 and 2027, the consideration from the disposal being contingent and receivable from January 2027 onwards, coupled with the operational issues with the Civil Service Pension Scheme contract and the impact this has had on the wider Pension Solutions business, post actions being taken across the wider Group to offset some of the impact (primarily the acceleration of the aforementioned overhead reduction into 2026), has reduced the forecast revenue, profit and cash flow in 2026. When combined with available committed facilities, the Group remains able to manage scheduled debt repayments (with no need for future refinancing of these repayments over the going concern period).

The most material sensitivities to the base case are the risk of not delivering the planned revenue growth, the overhead reduction being delayed or not delivered, progress to resolve the operational issues with the Civil Service Pension Scheme being slower than planned, and the delay or non-delivery of the aforementioned committed actions.

The base case projections used for going concern assessment purposes reflect business disposals completed up to the date of approval of the consolidated financial statements (including the disposal of the private sector contact centre disposal which completed on 31 July 2026).

The base case financial forecasts demonstrate liquidity headroom and compliance with all debt covenant measures throughout the going concern period to 31 December 2027.

In considering severe but plausible downside scenarios, the Board has taken account of the potential adverse financial impacts resulting from the following risks:

 

CAPITA HEALTH HOLDINGS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 15 -

Basis of Preparation (continued)

 

The likelihood of simultaneous crystallisation of the above risks at a sufficiently material magnitude is considered by the Board to be low. Nevertheless, there may be scenarios where a combination of the above risks crystallises and the Group would need to take action to ensure there is sufficient headroom when assessing the Group’s future compliance with its debt covenants. In its assessment of going concern, the Board has considered the mitigations, under the direct control of the Group, that could be implemented including, but not limited to, further reducing (or removing in full) bonus and incentive payments, reducing discretionary spend and reduction or delay in capital investment.

Taking these considerations into account, the Group’s financial forecasts, in a severe but plausible downside scenario, before taking account of any covenant waiver or amendment, demonstrate sufficient liquidity headroom throughout the going concern period to December 2027, but potentially insufficient headroom when assessing compliance with debt covenant measures in the short term. This was not the case when assessing the severe but plausible downside scenario for the purposes of the 31 December 2025 consolidated financial statements due to the combination of events in 2026 detailed further above. The Group’s financial forecasts, in a severe but plausible downside scenario demonstrate sufficient headroom when assessing compliance with debt covenant measures beyond the short term.

The Group maintains regular dialogue with its lenders, and the Board has confidence that any temporary waiver or amendment could be obtained, if required.

Material Uncertainty related to the Group

The Board recognises that any debt covenant waiver or amendment would require lender approval and is therefore outside the direct control of the Group. Accordingly, this gives rise to a material uncertainty, as defined by accounting standards, relating to events and circumstances which may cast significant doubt about the Group’s ability to continue as a going concern and to realise assets and discharge its liabilities in the normal course of business. These condensed consolidated financial statements do not include any adjustments that would result from the basis of preparation being inappropriate.

 

Adoption of going concern basis in the Group financial statements

Notwithstanding the material uncertainty described above, the Board has concluded that it remains appropriate to adopt the going concern basis in preparing these condensed consolidated financial statements. In reaching this conclusion, the Board has considered the Group’s financial forecasts and the mitigating actions available to the Group should the severe but plausible downside scenario materialise, including the potential for a debt covenant waiver or amendment. Accordingly, the Board has concluded that the Group will be able to continue in operation and meet its liabilities as they fall due over the period to 31 December 2027.

Conclusion

Although the Company has a reliance on the Group as detailed above, even in a severe but plausible downside, the Directors are confident the Company will continue to have adequate financial resources to continue in operation and discharge its liabilities as they fall due over the period to 31 December 2027. Consequently, the financial statements have been prepared on the going concern basis.

 

However, as the Group’s condensed consolidated financial statements have identified a material uncertainty giving rise to significant doubt over the Group’s ability to continue as a going concern, given the Company’s reliance on the Group, as set out above, this gives rise to a material uncertainty which may cast significant doubt about the Company’s ability to continue as a going concern and, therefore, that the Company may be unable to continue in operation and discharge its liabilities in the normal course of business. The financial statements do not include any adjustments which would be required if the going concern basis of preparation were to be deemed inappropriate.

CAPITA HEALTH HOLDINGS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 16 -
1.2
Compliance with accounting standards

The Company has applied FRS101 – Reduced Disclosure Framework in the preparation of its financial statements.

 

The Company has prepared and presented these financial statements by applying the recognition, measurement and disclosure requirements of international accounting standards in conformity with the requirements of the Companies Act 2006 .

 

The Company's ultimate parent company, Capita plc, includes the Company in its consolidated statements. The consolidated financial statements are prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 and with UK-adopted International Financial Reporting Standards ('UK-IFRSs') and the Disclosure and the Transparency Rules of the UK's Financial Conduct Authority. They are available to the public and may be obtained from Capita plc’s website on https://www.capita.com/investors .

 

In these financial statements, the Company has applied the disclosure exemptions available under FRS 101 in respect of the following disclosures:

 

Since the consolidated financial statements of Capita plc include equivalent disclosures, the Company has also taken the disclosure exemptions under FRS 101 available in respect of the following disclosure:

1.3
Change in accounting policies

The Company has adopted the new amendments to standards detailed below but they do not have a material effect on the Company's financial statements.

 

New amendments or interpretations                         Effective date

Lack of exchangeability – Amendments to IAS 21                    1 January 2025

1.4
Investments

The Company has investments in subsidiaries which are shown at cost, less provisions for impairment. Investments in subsidiaries are reviewed for impairment annually or more frequently if events or changes in circumstances indicate that the carrying value may be impaired.

 

The Company determines whether investments in subsidiaries are impaired based on impairment indicators. If an indicator is identified, an impairment test is performed. This involves estimation of the enterprise value of the investee which is calculated based on the discounted present value of estimated future cash flows, including the recoverable value of any subsidiaries held by the direct investment. The enterprise value of each investment is also adjusted for cash and other debt like items, including intercompany balances. The Company also assesses whether there are indicators to reverse previously recognised impairment losses. Reversals of impairment are only recognised where there has been a change in the estimates used to determine the investment’s recoverable amount since the last impairment loss was recognised.

CAPITA HEALTH HOLDINGS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 17 -
1.5
Financial instruments

Trade and other receivables

Trade receivables are initially recognised at cost (being the same as fair value) and subsequently at amortised cost less any provision for impairment, to ensure the amounts recognised represent their recoverable amount.

 

For trade receivables, the Company applies the simplified approach permitted by IFRS 9 Financial instruments, resulting in trade receivables recognised and carried at original invoice amount less an allowance for any uncollectible amounts based on expected credit losses. Where the carrying amount of an asset exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

 

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is derecognised (i.e removed from the Company’s balance sheet) when (i) the rights to receive the cash flows from the asset have expired; or, (ii) the Company has transferred its right to receive cash flows from the asset.

 

Trade and other payables

Trade and other payables are recognised initially at cost (being same as fair value). Subsequent to initial recognition they are measured at amortised cost using the effective interest method.

 

 

 

1.6
Taxation

Tax on the profit or loss for the year comprises current and deferred tax. Tax is recognised in the income statement except to the extent that it relates to items recognised directly in equity or other comprehensive income.

Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the balance sheet date, and any adjustment to tax payable in respect of previous years.

 

Deferred tax is provided, using the liability method, on all temporary differences at the balance sheet date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

 

Deferred tax assets are recognised for all deductible temporary differences, carry-forward of unused tax assets and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry-forward of unused tax assets and unused tax losses can be utilised, except where the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.

The carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised.

 

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the balance sheet date.

1.7
Group accounts

The financial statements present information about the Company as an individual company and not about its Group. The Company has not prepared Group accounts because it is fully exempt from the requirement to do so by section 400 of the Companies Act 2006 since it is a subsidiary company of Capita plc, a company incorporated in England and Wales, and is included in the consolidated financial statements of that company.

CAPITA HEALTH HOLDINGS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 18 -
1.8
Current versus non-current classification

The Company presents assets and liabilities in the balance sheet based on whether they are current or non-current.

 

An asset is current when it is:

All other assets are classified as non-current.

 

A liability is current when:

The Company classifies all other liabilities as non-current.

2
Significant accounting judgements, estimates and assumptions

The preparation of financial statements in conformity with generally accepted accounting principles requires the directors to make judgements and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingencies at the date of the financial statements and the reported income and expense during the reported periods. Although these judgements and assumptions are based on the Directors' best knowledge of the amount, events or actions, actual results may differ.

 

The key sources of estimation uncertainty that have a significant risk of causing material adjustment to the carrying amounts of assets and liabilities within the next financial year are the estimation of the recoverable amount of investments in subsidiaries. The Company determines whether investments in subsidiaries are impaired based on impairment indicators. If an indicator is identified, an impairment test is performed. This involves estimation of the enterprise value of the investee which is determined based on the greater of discounted future cash flows at a suitable discount rate or through the recoverable value of the investments held by the investee company.

3
Investment income
2025
2024
£
£
Dividend income from shares in subsidiary companies
-
0
27,140,282
-
0
27,140,282

In 2024, the Company received dividend in specie of £27,140,282 from its subsidiaries, Clinical Solutions Holdings Limited and Contact Associates Limited, settled via amounts due from Capita plc.

CAPITA HEALTH HOLDINGS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 19 -
4
Other income
2025
2024
£
£
Intercompany loan payable written back
-
52,000,013
-
0
52,000,013

In 2024, the Company recognised £52,000,000 on write‑back of an intercompany loan payable following a debt restructuring arrangement with its parent company, Capita Holdings Limited.

5
Impairments

Impairment tests have been carried out where appropriate and the following impairment losses have been recognised in profit or loss:

2025
2024
£
£
Impairment of investments in subsidiaries
-
0
101
-
101
6
Net finance income
2025
2024
£
£
Interest income
Interest receivable from Group companies
399,360
2,544,991
399,360
2,544,991
Interest expense
Interest expense on bank overdrafts and loans
-
0
(24,777)
-
0
(24,777)
Total net finance income
399,360
2,520,214
7
Income tax
The major components of income tax charge are:
2025
2024
£
£
Current tax
UK corporation tax
99,840
630,042
Adjustments in respect of prior periods
1
(4)
99,841
630,038
CAPITA HEALTH HOLDINGS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
7
Income tax
(Continued)
- 20 -

The reconciliation between tax charge and the accounting profit multiplied by the UK corporation tax rate for the years ended 31 December 2025 and 2024 is as follows:

2025
2024
£
£
Profit before taxation
399,360
81,660,364
Expected tax charge based on the weighted average Corporation Tax rate of 25.00% (2024: 25.00%)
99,840
20,415,091
Non-taxable income
-
0
(12,999,978)
Adjustment in respect of current income tax of prior periods
1
(4)
Non-taxable dividend income
-
(6,785,071)
Total adjustments
1
(19,785,053)
Total tax charge reported in the income statement
99,841
630,038
8
Investments
Subsidiaries
£
Cost
At 1 January 2025 & 31 December 2025
5,283,013
Net book value
At 31 December 2025
5,283,013
At 31 December 2024
5,283,013
9
List of Subsidiaries

Details of the company's subsidiaries at 31 December 2025 are as follows:

Name of company
Address
Class of
% Held
shares held
Direct
Contact Associates Limited
1
Ordinary
100.00

Registered office addresses (all UK unless otherwise indicated):

1
First Floor, 2 Kingdom Street, Paddington, London, W2 6BD
CAPITA HEALTH HOLDINGS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 21 -
10
Trade and other receivables
Current
2025
2024
£
£
Amounts due from Group companies
-
0
15,111,526
-
0
15,111,526
Non-current
2025
2024
£
£
Amount due from Group companies
1,005,872
-
0
1,005,872
-
0

Amounts due from Group companies are repayable on demand. These are not chargeable to interest except for the amounts due from Capita plc, on which interest is charged as per the prevailing Bank of England rates.

 

The Group undertook a review of the funding structure of its key subsidiaries during the second half of the year. Following this review, £1,005,872 of the Company’s receivables due from other Group companies were reclassified from current to non‑current. These balances remain repayable on demand, together with any accrued interest; however, based on the conclusions of the review undertaken, there is no longer the expectation that the Company will realise these amounts within twelve months of the balance sheet date.

11
Trade and other payables
Current
2025
2024
£
£
Amount due to Group companies
-
0
14,299,366
-
0
14,299,366

Amounts due to Group companies are repayable on demand and are not chargeable to interest.

CAPITA HEALTH HOLDINGS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 22 -
12
Employees

There were no employees during the year (2024: None).

13
Directors' remuneration

All directors are paid by other companies within the Capita Group. The Company has not paid any fees or other remuneration to the Group-based Directors related to the directorship role they provided to the Company as a part of their Group-wide executive management role. The Company has estimated that allocation of the qualifying services that these Group-based Directors provided to the Company is inconsequential.

14
Share capital
2025
2024
2025
2024
Number
Number
£
£
Allotted, called up and fully paid
Ordinary shares of £1 each
At 1 January
20,000
20,000
20,000
20,000
Capital reduction
(19,999)
-
(19,999)
-
At 31 December
1
20,000
1
20,000
15
Share premium
2025
2024
£
£
Ordinary shares of £1 each
At 1 January
1,980,000
1,980,000
Share premium reduction
(1,980,000)
-
0
At 31 December
-
0
1,980,000
16
Controlling party

The Company's immediate parent undertaking is Capita Holdings Limited, a company incorporated in England and Wales.

 

The Company's ultimate parent undertaking is Capita plc, a company incorporated in England and Wales. The accounts of Capita plc are available from the registered office at First Floor, 2 Kingdom Street, Paddington, London, England, W2 6BD.

17
Post balance sheet date events

There are no significant events which have occurred after the reporting period.

2025-12-312025-01-01Capita Corporate Director LimitedG Bate-WilliamsCapita Group Secretary LimitedfalseCCH SoftwareiXBRL Review & Tag 2022.20Company not entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companiesAccounts have not been prepared in accordance with the provisions of the small companies regime064133942025-01-012025-12-3106413394bus:Director12025-01-012025-12-3106413394bus:Director22025-01-012025-12-3106413394bus:CompanySecretary12025-01-012025-12-3106413394bus:RegisteredOffice2025-01-012025-12-3106413394bus:Agent12025-01-012025-12-31064133942025-12-31064133942024-01-012024-12-310641339412025-01-012025-12-310641339412024-01-012024-12-3106413394core:RetainedEarningsAccumulatedLosses2025-01-012025-12-31064133942024-12-3106413394core:Non-currentFinancialInstruments2025-12-3106413394core:Non-currentFinancialInstruments2024-12-3106413394core:CurrentFinancialInstruments2025-12-3106413394core:CurrentFinancialInstruments2024-12-3106413394core:ShareCapital2025-12-3106413394core:ShareCapital2024-12-3106413394core:SharePremium2025-12-3106413394core:SharePremium2024-12-3106413394core:RetainedEarningsAccumulatedLosses2025-12-3106413394core:RetainedEarningsAccumulatedLosses2024-12-3106413394core:SharePremium2023-12-3106413394core:RetainedEarningsAccumulatedLosses2023-12-31064133942023-12-3106413394core:ShareCapital2024-12-3106413394core:ShareCapital2023-12-3106413394core:SharePremium2024-12-3106413394core:ShareCapital2025-01-012025-12-3106413394core:SharePremium2025-01-012025-12-3106413394core:SharePremium2024-01-012024-12-3106413394core:ContinuingOperations2025-01-012025-12-3106413394core:CostValuation2024-12-310641339412025-01-012025-12-31064133942024-12-310641339412025-01-012025-12-3106413394bus:PrivateLimitedCompanyLtd2025-01-012025-12-3106413394bus:FRS1012025-01-012025-12-3106413394bus:AuditExempt-NoAccountantsReport2025-01-012025-12-3106413394bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP